TGA / PMDA / NMPA · Asia-Pacific
infiltrating — TGA / PMDA / NMPA regulatory status
infiltrating regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 6 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL | Phase 2 | Iovance Biotherapeutics | NCT03610490 |
| Tumor infiltrating lymphocytes (TIL) LN-145 | Phase 2 | Iovance Biotherapeutics | NCT04111510 |
| Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL) | Phase 1 | United Therapeutics Europe | NCT05768347 |
| Autologous tumor-infiltrating lymphocyte cells | Phase 1 | Chinese Academy of | NCT06334783 |
| The TILS001 trial | Phase 1 | George Institute for | 2024-511915-21-01 |
| VHIO20001 | Phase 1 | George Institute for | 2024-517021-12-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 12280140 | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy | US |
| 12233075 | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same | US |
| 12226434 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12194061 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12188048 | Restimulation of cryopreserved tumor infiltrating lymphocytes | US |
| 12121541 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12031157 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 12024718 | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 11998568 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
| 11975028 | Restimulation of cryopreserved tumor infiltrating lymphocytes | US |
| 11969444 | Restimulation of cryopreserved tumor infiltrating lymphocytes | US |
| 11939596 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of infiltrating?
infiltrating currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get infiltrating regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to infiltrating?
This spoke lists 6 published programs associated with infiltrating in our pipeline index.